Announced Wed, 21 Oct, 2026 · 17:04 IST

Gland Pharma to approve September 2026 quarterly results

Results View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹2930.00

prior close

₹2906.10

announcement price

After-mkt

timing

Nifty Smallcap 250market-1.1%-1.6% vs market

Pharmaceuticals peers, median of 170sector-0.5%-2.2% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Smallcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.6

15m

+0.9

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7-1.1-1.6-0.5-2.2

Next day

-3.9-3.9-0.1-2.2-1.8

-3.2-2.8-0.5-1.1-2.2

+0.7pendingpending+0.7+0.1

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma will hold a Board meeting on November 6, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. An investor and analyst call is scheduled for 6:30 PM IST on the same day. The trading window will reopen on November 9, 2026.

Likely market impact

This is only a meeting notice. No profit, revenue, debt, or cash-flow figures are provided, so the stock's direction cannot be assessed until results are released.